[go: up one dir, main page]

WO2025237757A1 - Système d'évaluation de la santé tissulaire - Google Patents

Système d'évaluation de la santé tissulaire

Info

Publication number
WO2025237757A1
WO2025237757A1 PCT/EP2025/062434 EP2025062434W WO2025237757A1 WO 2025237757 A1 WO2025237757 A1 WO 2025237757A1 EP 2025062434 W EP2025062434 W EP 2025062434W WO 2025237757 A1 WO2025237757 A1 WO 2025237757A1
Authority
WO
WIPO (PCT)
Prior art keywords
tissue
light
fdots
location
time
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/EP2025/062434
Other languages
English (en)
Inventor
Elvira Johanna Maria Paulussen
Loes Henrica Martina VAN DE KAMP-PEETERS
Matthias Born
Pieter HORSTMAN
Monique STOFFELS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Koninklijke Philips NV
Original Assignee
Koninklijke Philips NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Koninklijke Philips NV filed Critical Koninklijke Philips NV
Publication of WO2025237757A1 publication Critical patent/WO2025237757A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/0624—Apparatus adapted for a specific treatment for eliminating microbes, germs, bacteria on or in the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0033—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room
    • A61B5/0036—Features or image-related aspects of imaging apparatus, e.g. for MRI, optical tomography or impedance tomography apparatus; Arrangements of imaging apparatus in a room including treatment, e.g., using an implantable medical device, ablating, ventilating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0071—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by measuring fluorescence emission
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0082—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes
    • A61B5/0088—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes for oral or dental tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/01—Measuring temperature of body parts ; Diagnostic temperature sensing, e.g. for malignant or inflamed tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/44—Detecting, measuring or recording for evaluating the integumentary system, e.g. skin, hair or nails
    • A61B5/441—Skin evaluation, e.g. for skin disorder diagnosis
    • A61B5/445—Evaluating skin irritation or skin trauma, e.g. rash, eczema, wound, bed sore
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/45—For evaluating or diagnosing the musculoskeletal system or teeth
    • A61B5/4538—Evaluating a particular part of the muscoloskeletal system or a particular medical condition
    • A61B5/4542—Evaluating the mouth, e.g. the jaw
    • A61B5/4552—Evaluating soft tissue within the mouth, e.g. gums or tongue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
    • A61B5/6801—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
    • A61B5/6813—Specially adapted to be attached to a specific body part
    • A61B5/6814—Head
    • A61B5/682—Mouth, e.g., oral cavity; tongue; Lips; Teeth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
    • A61B5/14507—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue specially adapted for measuring characteristics of body fluids other than blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0601—Apparatus for use inside the body
    • A61N5/0603—Apparatus for use inside the body for treatment of body cavities
    • A61N2005/0606—Mouth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0626—Monitoring, verifying, controlling systems and methods
    • A61N2005/0627—Dose monitoring systems and methods
    • A61N2005/0628—Dose monitoring systems and methods including a radiation sensor

Definitions

  • a system for evaluating health of a tissue comprises: a light source adapted to transmit light having an excitation wavelength to the tissue.
  • the system also comprises a device comprising a material comprising fluorescing dots (Fdots) disposed therein.
  • the Fdots are adapted to fluoresce at an emission wavelength when the light having the excitation wavelength is incident thereon, and to terminate fluorescing in a presence of nitric oxide (NO).
  • the system also comprises a memory that stores instructions; and a processor that executes the instructions. When executed by the processor, the instructions cause the system to: adjust an output of the light source at the excitation wavelength to treat the tissue with the light at the emission wavelength based on a location of the NO and/or a time when the NO is present.
  • a method of evaluating a tissue comprises: transmitting light having an excitation wavelength to the tissue, wherein the excitation wavelength is in the optical spectrum; providing a device comprising a material comprising fluorescing dots (Fdots) disposed therein.
  • the Fdots are adapted to fluoresce at an emission wavelength with the light having the excitation wavelength is incident thereon, and to terminate fluorescing in a presence of nitric oxide (NO).
  • the method also comprises determining a location of the tissue where and/or a time when the NO is present; and adjusting the transmitting the light at the excitation wavelength to treat the tissue with the light at the emission wavelength based on the location and/or the time.
  • Fig. 1 is a conceptual view showing sources of inflammation, resulting in production of NO, and resulting adverse effects.
  • Fig. 2A is a perspective view of a mouthpiece comprising a material comprising fluorescing dots (Fdots) in accordance with a representative embodiment.
  • Fig. 2B is a graph showing Fdot size versus emission wavelength.
  • Fig. 3 is a graph showing onset of NO production in the presence of blue light having a wavelength of 450 nm versus time.
  • FIG. 4 is a simplified block diagram of a system for evaluating and/or treating oral tissue using an inventive mouthpiece, in accordance with a representative embodiment.
  • FIG. 5A is a conceptual view of a system for evaluating and/or treating oral tissue using an inventive device in accordance with a representative embodiment.
  • Fig. 5B is a flow chart of method for evaluating and/or treating oral tissue using an inventive device in accordance with a representative embodiment.
  • FIG. 6A is a conceptual view of a system for evaluating and/or treating oral tissue using an inventive device in accordance with a representative embodiment.
  • Fig. 6B is a flow chart of method for evaluating and/or treating oral tissue using an inventive device in accordance with a representative embodiment.
  • the system is adapted to treat regions where inflammation exists in the tissue.
  • the system is adapted to not only detect the presence of inflammation in tissue, but also is adapted to provide treatment to the inflamed area and/or detect the effect of the treatment.
  • the devices of the various representative embodiments comprise fluorescent dot (Fdots) including so-called polymer dots (Pdots) and quantum dots (Qdots).
  • the materials selected for the Fdots is adapted to emit fluorescent light when light of a certain wavelength is incident on the Fdots.
  • the light that causes the fluorescent emission from the Fdots is referred to herein as an excitation light having an excitation wavelength.
  • the light emitted from the Fdots during fluorescence is referred to herein as emission light and has an emission wavelength.
  • the excitation wavelength is selected to provide treatment to inflamed tissue.
  • Fdots are selected so that in the presence of RNS including NO, and ROS, the fluorescent emission terminates. These Fdots may be referred to herein as “turn-off’ Fdots.
  • the Fdots are selected to fluoresce in the presence of RNS or ROS. These Fdots may be referred to herein as “turn-on” Fdots.
  • the systems of the various representative embodiments function to detect RNS and ROS, which, as described more fully below, is indicative of such inflammation.
  • this detection provides not only the location of inflammation, but also the time of the detection.
  • the emission light is used not only to detect RNS or ROS, but also to treat the inflamed tissue.
  • the output of the light source used for treating the inflamed tissue may be altered to better treat the inflammation.
  • the Fdots may be used to monitor the progress of treatment of a condition. Specifically, as the treated tissue heals, the inflammation is reduced, and the production of NO decreases. In a representative embodiment, as the presence of NO decreases, and the fluorescent emission caused by the excitation light source increases providing a measure of the progress of the treatment. Accordingly, and among other improvements to the field of medical diagnosis and treatment, the present teachings enable the detection and monitoring of inflammation in tissue including internal and external tissue, monitoring of the progress of a treatment, and adaptation of treatment of tissue based on the monitoring.
  • Fig. 1 is a conceptual view showing sources of inflammation 101 in a region of tissue, resulting in production of NO, and resulting adverse effects.
  • the tissue that is inflamed is gingivival tissue (e.g., gums), and the indicator of inflammation is NO.
  • gingivival tissue e.g., gums
  • the indicator of inflammation is NO.
  • the tissue is not limited to the gums, and other tissue, such as skin, which is susceptible to inflammation, emits RNS or ROS when inflamed, and is beneficially treated with light are contemplated.
  • the progress of treatment of tissue can be monitored using Fdots of various representative embodiments.
  • the inflammation 101 which can result in different layers of tissue, may be caused by infection 102 or injury 104.
  • the sources of injury are diverse, including but not limited to exposure to UVA radiation, UV-induced erythema, wound healing or other injury.
  • the inflamed layers of skin can release NO.
  • NO exists in vivo as a dissolved free radical gas comprising an unpaired electron on the Nitrogen that can inflict cellular damage under prolonged inflammation.
  • NO can cause DNA damage 106, protein modification 108 and apoptosis 110, as well as other possible deleterious effects on the body.
  • excessive NO levels during inflammation can lead to detrimental effects like protein nitration, DNA damage and programmed cell death.
  • the presence of NO in tissue signals inflammation, and as described more fully below, is detected not only to determine the location and/or time of inflammation, but also to determine the location and dose of treatment of the inflamed tissue useful given the condition of the tissue.
  • the devices of the various representative embodiments may be used to monitor the light treatment in real-time. For example, the devices of the various representative embodiments can be used to determine when the light treatment is too intense and/or applied for too long. In this case, the light treatment can be reduced to avoid tissue damage.
  • FIG. 2A is a perspective view of a mouthpiece 201 comprising a material 204 comprising fluorescing dots (Fdots) 202 in accordance with a representative embodiment. It is again emphasized that the use of Fdots in a mouthpiece for oral use is merely illustrative, and applications to other tissue are contemplated with appropriate safeguards as described more fully below.
  • Fdots fluorescing dots
  • the areas of the tissue where inflammation exists can be treated with light of a particular wavelength useful in treating the underlying condition.
  • the Fdots may be used to monitor the progress of treatment of a condition. Specifically, as the treated tissue heals, the inflammation is reduced, and the production of NO decreases. As the presence of NO decreases, and the fluorescent emission caused by the excitation light source increases providing a measure of the progress of the treatment. Accordingly, in oral applications Fdot signal response to light- induced NO production provides a measure of light treatment status of the oral tissue (e.g., gum) that can be used to determine both the treatment and the progress of the treatment. In such way, severe inflammation (e.g., periodontitis) in the mouth can effectively be treated locally and the light treatment can be adapted and targeted to aim for better safety and effectiveness in a personalized way.
  • the oral tissue e.g., gum
  • Another beneficial aspect of the various representative embodiments includes the improved ability to monitor the temperature of the tissue.
  • the temperature is used to identify areas where tissue damage is imminent. These known methods provide only a course measure, with a threshold of 43 °C being the benchmark above which damage can occur.
  • one source of inflammation can be the applied radiation (light) used in the treatment of the tissue.
  • the devices and systems of the various representative embodiments are adapted to provide a more accurate measure of the change in the temperature of the tissue undergoing treatment and more promptly. Specifically, by monitoring the rise in the temperature, the applied light dose could be altered before the temperature reaches a dangerous level. So, in addition to monitoring existing inflammation and adapting the light treatment using devices and systems of various representative embodiments, the present teachings contemplate monitoring the change in temperature caused by the treatment, and adjusting the treatment to avoid deleterious impact on the tissue.
  • the Fdots 202 are selected from a number of materials adapted to cause fluorescent emission at a particular wavelength, and to terminate emission in the presence of a particular RNS or ROS.
  • the “termination” of emission may vary.
  • the emission reduces gradually or partly for example by including Fdots comprising different materials that can impact the spectra, sensitivity and specificity to provide a gradual output signal from the Fdots.
  • the degree of termination of fluorescent emission is related linearly or non-linearly to the concentration of NO.
  • the correlation between output (emission) signal and NO concentration may not always be initially obvious, and certain transformations and calculations may be required to get to relation between fluorescent emission signal and NO concentration.
  • the Fdots are chosen to fluoresce in the presence of RNS or ROS.
  • the initiation of emission will vary.
  • emission starts immediately and the Fdots function as an on-off switch.
  • the emission starts gradually.
  • the degree of commencement of fluorescent emission may also be related to the concentration of NO.
  • NO concentration can be made to gradually change fluorescence (emission) intensity, but also other factors including reaction time may play a role.
  • the excitation wavelength or the emission can be selected for treating tissue with light therapy.
  • the Fdots comprise Qdots.
  • Quantum dots are nanoscale crystals with optical and electric properties. They can emit or absorb specific wavelengths.
  • Qdot biosensors are developed as fluorescence sensor for NO. The sensor emits fluorescent light when excited by visible (e.g., blue) light and turns off fluorescence when NO is present meaning the Qdots will code for a visual signal response in the presence of NO.
  • Qdots comprise a material having a valence band and a conduction band separated by an energy gap that depends on the nature and the size of the material.
  • the electrons After the absorption of light having a particular wavelength/energy, the electrons are excited to the conduction band, leaving a hole in the valence band.
  • the photo-generated electron-hole pair is known as an exciton, which, upon recombination, gives rise to the fluorescence emission.
  • Qdot materials One drawback to certain known Qdot materials is their inclusion of heavy metals. Heavy metals can be toxic, and as such may not be useful in applications to internal tissues (e.g., the gums). As such, in certain applications, Qdots materials comprising heavy metals cannot be used. However, in other applications, the material 204 is selected to encapsulate the Qdot material comprising the heavy metal in a biocompatible material (e.g., polymer or silicone) that are beneficially permeable to NO to render its use safe in internal applications.
  • a biocompatible material e.g., polymer or silicone
  • Qdots comprising heavy metals may, however, be used in applications that are not internal, such as the skin.
  • the Qdots usefully provide an indication of the presence and concentration of NO, which in turn is indicative of inflammation caused by a skin disease or injury.
  • Qdots that do not comprise heavy metals are also contemplated. These Qdots are generally not toxic and therefore may be used in internal applications, such as mouthpiece 201. Qdots contemplated for use in such internal applications comprise, but are not limited to Silicon Qdots, Carbon Qdots and Graphene Qdots. These materials are nanocrystals embedded in a polymer matrix (e.g., material 204)
  • Silicon Qdots lend greater biocompatibility and provide certain optical properties, such as long-lived excited states, large Stokes shift and tunable luminescence that can be beneficial in certain applications.
  • Carbon Qdots also lend greater biocompatibility due to their nontoxicity, while providing comparatively greater optical absorptivity, chemical stability and comparatively easy synthesis. Like Silicon Qdots, the fluorescence of Carbon Qdots is more efficient than many other materials, and thus lends itself to improved detection of NO, treatment of inflamed tissue, and monitoring of the progress of treatment of tissue.
  • Graphene Qdots when properly treated can also be used in vivo.
  • Graphene Qdots comprise a layer of graphene and are chemically and physically comparatively stable.
  • Graphene Qdots exhibit fluorescence emission across a comparatively large spectral range, including UV radiation, visible light an infrared (IR) radiation.
  • the Qdots may comprise a fluorescent molecularly engineered material comprising with iron(III) dithiocarbamates; Cadmium Selenium-Zinc Sulfur (CdSe-ZnS) nanocrystals; and surface bound tris(/V- (dithiocarboxy)sarcosine)iron(III).
  • “turn-on” Qdots may comprise CdSe-ZnS nanocrystals as fluorophores and surface bound tris(N-(dithiocarboxy)sarcosine)iron(III) as reactive centers for NO.
  • both Qdots that emit light in the presence of NO and Qdots that terminate emission in the presence of NO are contemplated. These Qdots are referred to as “turn-on/turn-off ’ Qdots.
  • the following materials are contemplated for use as “turn-on/turn-off’ Qdots useful in the detection of NO: Fe +3 ; group II materials (alkyl metals, metal oxides or organic salts) with the use of an inorganic shell (e.g., ZnS); and group VI materials (Se, S and Te) with the use of an inorganic shell (e.g., ZnS).
  • the areas of the skin where inflammation exists can be treated with light of a particular wavelength useful in treating the underlying condition.
  • the Fdots may be used to monitor the progress of treatment of a condition. Specifically, as the treated tissue heals, the inflammation is reduced, and the resulting production of NO decreases. As the presence of NO decreases, when the Fdots are “turn-off’ Fdots, the fluorescent emission caused by the excitation light source increases. By contrast, when “turn-on” Fdots are used, as the treated tissue heals, the inflammation is reduced, and the production of NO decreases.
  • the Fdots As the presence of NO decreases, when the Fdots are “turn-on”, the fluorescent emission caused by the excitation light source decreases. Moreover, in certain representative embodiments such as described below in connection with Figs. 5A-5B, the Fdots emit light of one wavelength when light of an excitation wavelength is incident thereon, and emits light of a different wavelength in the presence of NO.
  • the Fdots 202 are polymer dots (Pdots).
  • Pdots polymer dots
  • Pdots comprise organic nanoparticles (e.g., semiconducting polymer nanoparticles (SPNs)) assembled from polymer chains with - conjugated systems.
  • SPNs semiconducting polymer nanoparticles
  • Pdots may consist of hydrophobic semiconducting polymers with a volume or weight fraction more than 50% and a diameter generally less than 50 nm, sometimes the particles size can be less than 30 nm. Pdots have shown characteristics of large absorption cross section, high brightness, good photostability, low toxicity. Moreover, Pdots provide comparatively high fluorescence brightness under both one photon and two-photon stimulation, and therefore are useful in biosensing and treatment applications such as those described in connection with various representative embodiments described herein.
  • certain Pdots emit fluorescent light when excited by visible blue or violet light and turn off fluorescence when nitric oxide (NO) is present. Moreover, certain Pdots emit fluorescent light when excited by visible blue or violet light and emit fluorescent light of a different wavelength (e.g., near infra-red (NIR) when nitric oxide (NO) is present. As such, Pdots will code for a visual signal response in the presence of NO.
  • NIR near infra-red
  • the areas of the skin where inflammation exists can be treated with light of a particular wavelength useful in treating the underlying condition.
  • the Pdots may be used to monitor the progress of treatment of a condition. Specifically, as the treated tissue heals, the inflammation is reduced, and the production of NO decreases. As the presence of NO decreases, the fluorescent emission caused by the excitation light source increases. Alternatively, in certain other representative embodiments, when the presence of NO decreases, the fluorescent emission decreases.
  • Fig. 2B is a graph showing Fdot size versus emission wavelength.
  • different Fdot materials have different excitation and emission wavelengths.
  • the size of the Fdots varies depending on the material selected.
  • the emission wavelength increases with increasing Fdot size (volume).
  • the size of the Fdot as a function of emission wavelength is useful.
  • the size of the Fdots used in the representative embodiments of Figs. 5A-5B are smaller than the size of the Fdots used in the representative embodiments of Figs. 6A-6B.
  • the size of the Fdots contemplated for use in accordance with devices of the various representative embodiments are comparatively small.
  • the Fdot sensors size lend easily for adaptation into mouthpieces or other devices for medical diagnosis and treatment.
  • the level of response can be collected by integrated sensors that are small enough to be captured by the mouthpiece comprising a plurality of Fdots is improved compared to certain known devices and systems.
  • Fig. 3 is a graph showing onset of NO production in the presence of blue light having a wavelength of 450 nm versus time. Specifically, the blue light is applied to the tissue for a period of time, and the resultant peaks of NO are detected.
  • First curve 302, second curve 304, third curve 306 and fourth curve 308 are measures of the concentration of NO at times of sampling with the fourth curve 308 indicative of the cessation of illumination has stopped, and shows that NO is still released from skin for a time after illumination is terminated.
  • light-induced NO production can serve as a ‘memory system’ of treated positions of tissue and according to various representative embodiments, light treatment can be adapted and targeted to aim for better safety and effectiveness.
  • FIG. 4 is a simplified block diagram of a system 400 for evaluating and/or treating oral tissue using an inventive mouthpiece, in accordance with a representative embodiment.
  • Various aspects and details of presently described system may be common to those described in connection with representative embodiments above, and may be used in systems of representative embodiments described below. These common aspects and details may not be repeated in order to avoid obscuring the presently described representative embodiments.
  • the system 400 comprises a mouthpiece 401, which comprises a plurality of Fdots disposed in a suitable material. It is emphasized the mouthpiece 401 is merely an illustrative device, and other devices are contemplated for use in connection with the system 400. Moreover, these alternative devices are contemplated for both internal and external use with appropriate materials and devices based on the application. Just by way of illustration, and as noted below, instead of the mouthpiece 401, the device may be adapted to monitor and/or treat skin conditions that are responsive to light treatment including, for example inflammatory skin diseases or injuries such as overexposure to UV radiation.
  • the system 400 comprises a detector 402.
  • the detector 402 is selected to detect the presence of RNS or ROS.
  • the detector 402 is adapted to detect the presence of NO.
  • the detector 402 is adapted to determine the location and time of the presence of NO.
  • different types of detectors are contemplated.
  • the detector 402 comprises a pixelated (ID, 2D or 3D) charge coupled device (CCD) or a complementary metal oxide semiconductor (CCD) device.
  • the detector 402 detects NO by monitoring the chemiluminescence of the reaction of NO with ozone.
  • the detector 402 may comprise electrochemical sensors, including for example, but not limited to differential pulse voltametric (DPV) or diphenyl phosphate (DPP) electrochemical sensors. In yet other embodiments, the detector 402 may comprise a photoacoustic sensor.
  • DPV differential pulse voltametric
  • DPP diphenyl phosphate
  • the system 400 also comprises a light source 404.
  • the light source 404 is selected to provide an excitation wavelength to cause fluorescent emission from the Fdots as described above, or to provide light of a selected wavelength for treatment of the tissue as alluded to above and as described more fully below.
  • the light source 404 is also adapted to modify the intensity of light incident on the mouthpiece 401 and/or the tissue undergoing treatment, and/or the time of the application of light to the tissue, as described below.
  • the modification of the applied light from the light source 404 may carried out in a number of ways based on data the output from the detector 402.
  • data from the detector 402 is adapted enable measurements of NO concentration relative to a threshold.
  • the instructions based on data from the detector 402, the instructions cause the system 400 to determine the location where and/or the time when, a concentration of the NO is greater than a threshold. Based on this predetermined threshold, the instructions may cause the system 400 to adjust the intensity and/or duration of light from the light source.
  • the threshold may be in a range of approximately 30 parts-per-billion (ppb) and approximately 300 ppb NO. Moreover, the threshold may be set to indicate the level of NO is not existent. For example, the NO may be deemed not present when the concentration of the NO is below approximately 20 ppb.
  • the adjustment of the light source 404 may be iterative in accordance with certain representative embodiments. For example, after an adjustment of the light source 404 based on the data from the detector, the location is a first location, the time is a first time, and the instructions further cause the system to determine a second location where and/or a second time when the concentration of the NO is greater than the threshold; and further adjust the output of the light source at the excitation wavelength based on the second location and/or the second time.
  • Data from the detector 402 are provided to a controller 403.
  • the controller 403 comprises a processor 405, and a memory 407, which stores computer-executable instructions (code).
  • these instructions when executed by the processor 405 carry out various functions of representative embodiments described herein.
  • the memory 407 may store a set of software instructions that can be executed by the processor 405 to cause the system 400 to perform some or all aspects of certain methods or computer-based functions described herein.
  • the controller 403 may be implemented by a computer that includes more elements than the controller 403 and memory 407 of Fig. 4.
  • the controller 403 may be remote to the system 400, and is adapted to control various aspects of the system 400 remotely via connections including both wired and wireless connections and protocols.
  • the controller 403, at least in part is a specialty or particular computer useful in controlling the system 400.
  • the controller 403 may operate as a standalone device or may be connected, for example, using a network to other computer systems or peripheral devices.
  • the system 400 performs logical processing based on digital signals received via an analog-to- digital converter.
  • the controller 403 can also be implemented as or incorporated into various devices, such as a workstation that includes a controller, a stationary computer, a mobile computer, a personal computer (PC), a laptop computer, a tablet computer, or any other machine capable of executing a set of software instructions (sequential or otherwise) that specify actions to be taken by that machine.
  • the controller 403 can be incorporated as or in a device that in turn is in an integrated system that includes additional devices.
  • the controller 403 can be implemented in a device that also provides video or data communication. Moreover, the controller 403 may be connected to components of the system via a local wired interface such as an Ethernet cable or via a local wireless interface such as a Wi-Fi connection.
  • the processor 405 may be considered a representative example of a processor of the controller 403 and executes instructions to implement some or all aspects of methods and processes described herein.
  • the processor 405 is tangible and non-transitory.
  • the term “non-transitory” is to be interpreted not as an eternal characteristic of a state, but as a characteristic of a state that will last for a period.
  • the term “non-transitory” specifically disavows fleeting characteristics such as characteristics of a carrier wave or signal or other forms that exist only transitorily in any place at any time.
  • the processor 405 is an article of manufacture and/or a machine component.
  • the processor 405 is configured to execute software instructions to perform functions as described in the various embodiments herein.
  • the processor may be a general-purpose processor or may be part of an application specific integrated circuit (ASIC).
  • the processor may also be a microprocessor, a microcomputer, a processor chip, a controller, a microcontroller, a digital signal processor (DSP), a state machine, or a programmable logic device.
  • the processor may also be a logical circuit, including a programmable gate array (PGA), such as a field programmable gate array (FPGA), or another type of circuit that includes discrete gate and/or transistor logic.
  • the processor may be a central processing unit (CPU), a graphics processing unit (GPU), or both. Additionally, any processor described herein may include multiple processors, parallel processors, or both. Multiple processors may be included in, or coupled to, a single device or multiple devices.
  • processor encompasses an electronic component able to execute a program or machine executable instruction. References to a processor should be interpreted to include more than one processor or processing core, as in a multi-core processor. A processor may also refer to a collection of processors within a single computer system or distributed among multiple computer systems, such as in a cloud-based or other multi-site application.
  • Memory is an example of computer-readable storage media, and should be interpreted as possibly being multiple memories or databases.
  • the memory or database may for instance be multiple memories or databases local to the computer, and/or distributed amongst multiple computer systems or computing devices.
  • a computer readable storage medium is defined to be any medium that constitutes patentable subject matter under 35 U.S.C. ⁇ 101 and excludes any medium that does not constitute patentable subject matter under 35 U.S.C. ⁇ 101.
  • Examples of such media include non-transitory media such as computer memory devices that store information in a format that is readable by a computer or data processing system. More specific examples of non-transitory media include computer disks and non-volatile memories.
  • the memory 407 may include a main memory and/or a static memory, where memories in the system 400 communicate with each other and the processor via a bus (not shown).
  • the memory may be considered a representative example of a memory of the controller 403, and store instructions used to implement some or all aspects of methods and processes described herein.
  • Memories described herein are tangible storage mediums for storing data and executable software instructions and are non-transitory during the time software instructions are stored therein. As used herein, the term “non-transitory” is to be interpreted not as an eternal characteristic of a state, but as a characteristic of a state that will last for a period.
  • non- transitory specifically disavows fleeting characteristics such as characteristics of a carrier wave or signal or other forms that exist only transitorily in any place at any time.
  • the memory is an article of manufacture and/or machine components.
  • the memory is a computer-readable medium from which data and executable software instructions can be read by a computer (e.g., by the processor of the controller 403).
  • the memory may be implemented as one or more of randomaccess memory (RAM), read only memory (ROM), flash memory, electrically programmable read only memory (EPROM), electrically erasable programmable read-only memory (EEPROM), registers, a hard disk, a removable disk, tape, compact disk read only memory (CD- ROM), digital versatile disk (DVD), floppy disk, Blu-ray disk, or any other form of storage medium known in the art.
  • RAM randomaccess memory
  • ROM read only memory
  • EPROM electrically programmable read only memory
  • EEPROM electrically erasable programmable read-only memory
  • registers a hard disk, a removable disk, tape, compact disk read only memory (CD- ROM), digital versatile disk (DVD), floppy disk, Blu-ray disk, or any other form of storage medium known in the art.
  • the memory may be volatile or non-volatile, secure and/or encrypted, unsecure and/or unencrypted.
  • inventive concepts also encompass a computer readable medium that stores instructions
  • a computer readable medium is defined herein to be any medium that constitutes patentable subject matter under 35 U.S. C. ⁇ 101 and excludes any medium that does not constitute patentable subject matter under 35 U.S. C. ⁇ 101.
  • Examples of such media include non- transitory media such as computer memory devices that store information in a format that is readable by a computer or data processing system. More specific examples of non-transitory media include computer disks and non-volatile memories.
  • the memory 407 is an example of a computer-readable storage medium.
  • Computer memory is any memory which is directly accessible to a processor. Examples of computer memory include, registers, and register files. References to “memory” should be interpreted as possibly being multiple memories. The memory may for instance be multiple memories within the same computer system. The memory may also be multiple memories distributed amongst multiple computer systems or computing devices.
  • Software instructions when executed by the processor, perform one or more steps of the methods and processes as described herein. In an embodiment, the software instructions may reside all or in part within the memory and/or the processor during execution by the controller 403.
  • the system 400 may also comprise a display 406 connected to the controller 403.
  • the display 406 comprises a graphic user interface (GUI) and is connected to the controller 403 via a local wired interface such as an Ethernet cable or via a local wireless interface such as a Wi-Fi connection.
  • GUI graphic user interface
  • the display 406 may be a monitor such as a computer monitor, a display on a mobile device, an augmented reality display, a television, an electronic whiteboard, or another screen configured to display electronic imagery.
  • the controller 403 may be interfaced with other user input devices by which users can input instructions, including mouses, keyboards, thumbwheels and so on.
  • the controller 403 may also include one or more input interface(s) such as those noted above that may connect to other elements or components, as well as an interactive touch screen configured to display prompts to users and collect touch input from users. These interfaces may also be icons (not shown) on a display (not shown in Fig. 4 via the GUI.
  • the display 406 enables the user to determine the presence and/or levels of RNS (e.g., NO) based on data from the detector 402, and enables the user (e.g., using the GUI or other interface) to provide inputs from the controller 403 to the light source 404.
  • RNS e.g., NO
  • the inputs provided to the light source may alter the duration, or location, or intensity, or a combination thereof, of light applied by the light source 404 based on data from the detector 402.
  • the instructions in the memory 407 may cause the processor to alter the duration, or location, or intensity, or a combination thereof, of light applied by the light source based on data from the detector.
  • FIG. 5A is a conceptual view of a system 500 for evaluating and/or treating oral tissue using an inventive device in accordance with a representative embodiment.
  • Various aspects and details of presently described system may be common to those described in connection with representative embodiments above, and may be used in systems of representative embodiments described below. These common aspects and details may not be repeated in order to avoid obscuring the presently described representative embodiments.
  • a mouthpiece 501 is shown for reference, and is used to monitor and/or treat gums 506 of a subject’s mouth.
  • a portion of the mouthpiece is enlarged to show the Fdots 502 disposed in a material 504 as shown.
  • the portion comprising Fdots 502 in material 504 may be crafted to be used to monitor other internal tissue, or external tissue, such as skin tissue.
  • light 512 is incident from a light source (not shown in Fig. 5A) on a wavelength dependent beamsplitter 516.
  • the beamsplitter 516 is adapted to reflect the light 512 towards the portion.
  • the light 512 has a first wavelength selected to treat the tissue by transmission through the material 504, and to cause fluorescent emission 514 from the Fdots at second wavelength, which is different from the first wavelength.
  • the first wavelength is the excitation wavelength because it causes fluorescent emission, and is selected to treat the inflammation in the tissue as described above.
  • the excitation wavelength of the light 512 is violet or blue visible light, although other wavelengths are contemplated to carry out the excitation of the Fdots while at the same time providing the therapeutic light treatment of the particular tissue and the particular cause of the inflammation.
  • NO 510 emanates from the tissue (e.g., gums 506) and traverses the portion comprising the Fdots 502 disposed in the material 504.
  • the fluorescent emission 514 by the Fdots 502 terminates, and as described below, this termination of fluorescent emission 514 by the Fdots 502 allows the locations of NO production resulting from inflammation and/or non-inflammatory processes such as from light therapy on the tissue to be determined, and the time at which the inflammation exists, as may be desired.
  • the wavelength of the fluorescent emission 514 traverses the beamsplitter 516 unimpeded, and is incident on a charge-coupled device (CCD) camera 518.
  • CCD charge-coupled device
  • the second wavelength is the emission wavelength.
  • the Fdots 502 are selected to comprise a material that emits fluorescent radiation having a first wavelength when light of the excitation wavelength is incident thereon, and emits fluorescent radiation of a second (different) wavelength in the presence of NO.
  • the emission wavelength of the fluorescent emission 514 is near-infrared (NIR), although other wavelengths are contemplated to carry out the excitation of the Fdots.
  • the fluorescent emission 514 is incident on the CCD camera, which identifies the regions where and when NO is present, but also by where and when NO is absent. Specifically, the CCD camera records areas/times of the gums 506/tissue where light of the emission wavelength is present, and by absence where areas/times where the light of the emission wavelength is absent. Stated somewhat differently, light 512 is adapted to be incident on particular portion of the gums 506/tissue being monitored and/or treated. In regions of the portion of the gums 506 where NO is present, the fluorescent emission 514 terminates, and in regions where NO is not present, the fluorescent emission 514 continues caused by the light 512.
  • these data are recorded, and provided to the controller 403 so the processor 405 can alter the output of the light source to provide light 512 to treat regions where the inflammation of the tissue exists.
  • these data from the CCD camera 508 can also be used to monitor the progress of treatment of the tissue by the light 512.
  • the processor 405 can alter the output of the light source so that light of a particular intensity is applied for a particular time to provide the needed light treatment.
  • Fig. 5B is a flow chart of method for evaluating and/or treating oral tissue using an inventive device in accordance with a representative embodiment.
  • Various aspects and details of presently described system may be common to those described in connection with representative embodiments above, and may be used in systems of representative embodiments described below. These common aspects and details may not be repeated in order to avoid obscuring the presently described representative embodiments.
  • the method begins at 520 with the application of light 512 from the light source.
  • NO production exists.
  • the NO production may arise not only from inflammation in the tissue being treated, but also from the applied light.
  • fluorescence initiates due to the presence of the NO.
  • data from the CCD camera are used to determine spatial (and if desired) temporal aspects of the inflammation.
  • the processor 405 can alter the output of the light source so that light of a particular intensity is applied for a particular time to provide the appropriate light treatment.
  • these data from the CCD camera 508 can also be used to monitor the progress of treatment of the tissue by the light 512.
  • these data may also be used to monitor the temperature of the tissue under treatment as noted above.
  • Table 530 lists various parameters that can be stored in memory 407 to select the appropriate intensity and duration of the treatment. These factors include, but are not limited to, skin tone/baseline levels, inflammation level and boundary conditions.
  • these parameters stored in a look-up table in memory and based on the NO levels and locations, adjustments of the treatment light are carried out.
  • a light intensity level and duration are assigned, and through execution of instructions stored in memory, the processor 405 causes the light source to adjust the location, and/or intensity, and/or duration of the treatment light applied.
  • locations where a subject indicates a location a certain symptom e.g., sore or swollen gums
  • locations where a subject indicates a location a certain symptom may be provided (e.g., via the GUI or other interface).
  • the processor 405 causes the light source to adapt the location and/or intensity to ensure a particular treatment is carried out at a particular.
  • subject-specific data e.g., pain threshold
  • execution of instructions by the processor 405 can cause the adaptation of the light source to carry out a treatment having an appropriate intensity and duration based on the subject-specific data.
  • FIG. 6A is a conceptual view of a system for evaluating and/or treating oral tissue using an inventive device in accordance with a representative embodiment.
  • Various aspects and details of presently described system may be common to those described in connection with representative embodiments above, and may be used in systems of representative embodiments described below. These common aspects and details may not be repeated in order to avoid obscuring the presently described representative embodiments.
  • a mouthpiece 601 is shown for reference, and is used to monitor and/or treat gums 606 of a subject’s mouth.
  • a portion of the mouthpiece is enlarged to show the Fdots 602 disposed in a material 604 as shown.
  • the portion comprising Fdots 602 in material 604 may be crafted to be used to monitor other internal tissue, or external tissue, such as skin tissue.
  • light 612 is incident from a light source (not shown in Fig.
  • the light 612 has a wavelength selected to cause fluorescent emission 614 from the Fdots 602.
  • the light 612 is the excitation wavelength because it causes fluorescent emission 614.
  • the wavelength of light of the fluorescent emission 614 is blue and is selected to treat the inflammation in the tissue as described above.
  • the excitation wavelength of the light 612 is violet, although other wavelengths are contemplated to carry out the excitation of the Fdots 602 while at the same time providing the therapeutic light treatment of the particular tissue and the particular cause of the inflammation.
  • NO 610 emanates from the tissue (e.g., gums 606 and traverses the portion comprising the Fdots 602 disposed in the material 604.
  • the Fdots 602 are selected to comprise a material that not only fluoresces when light of the excitation wavelength is incident thereon, but also to terminate fluorescent emission by the Fdots 602 in the presence of NO when turn-off Fdots are implemented, or initiate fluorescent emission in when turn-on Fdots are implemented.
  • the detector 402 is adapted to determine the level of NO in the region around the tissue. These data are recorded, and provided to the controller 403 so the processor 405 can alter the output of the light source to provide light 612 to treat regions where the inflammation of the tissue exists. Moreover, and as alluded, these data can also be used to monitor the progress of treatment of the tissue by the light 612. Based on these data, the processor 405 can alter the output of the light source so that light of a particular intensity is applied for a particular time to provide the needed light treatment. Finally, these data may also be used to monitor the temperature of the tissue under treatment as noted above.
  • Fig. 6B is a flow chart of method for evaluating and/or treating oral tissue using an inventive device in accordance with a representative embodiment.
  • Various aspects and details of presently described system may be common to those described in connection with representative embodiments above, and may be used in systems of representative embodiments described below. These common aspects and details may not be repeated in order to avoid obscuring the presently described representative embodiments.
  • the method begins at 620 with the application of light 612 from the light source.
  • NO production exists.
  • the NO production may arise not only from inflammation in the tissue being treated, but also from the applied light.
  • fluorescence terminates due to the presence of the NO caused by inflammation and/or absorption of blue light.
  • data from the detector 402 are used to determine concentration of NO near the tissue being treated, and based on these data, the degree of inflammation can be determined.
  • the processor 405 can alter the output of the light source so that light of a particular intensity is applied for a particular time to provide the appropriate light treatment.
  • these data from the detector can also be used to monitor the progress of treatment of the tissue by the light 612. Finally, these data may also be used to monitor the temperature of the tissue under treatment as noted above.
  • Table 630 lists various parameters than can be stored in memory 407 to select the appropriate intensity and duration of the treatment. These factors include, but are not limited to, skin tone/baseline levels, inflammation level and boundary conditions. In accordance with a representative embodiment, these parameters stored in a look-up table in memory, and based on the NO levels and locations, adjustments of the treatment light are carried out. So, just by way of illustration, in accordance with a representative embodiment, for a given set of skin tone/inflammation/boundary conditions stored in memory (e.g., in a look-up table), a light intensity level and duration are assigned, and through execution of instructions stored in memory, the processor 405 causes the light source to adjust the location, and/or intensity, and/or duration of the treatment light applied.
  • locations where a subject indicates a location a certain symptom may be provided in the GUI or other interface.
  • the processor 405 causes the light source to adapt the location and/or intensity to ensure a particular treatment is carried out.
  • subject-specific data e.g., pain threshold
  • execution of instructions by the processor 405 can cause the adaptation of the light source to carry out a treatment having an appropriate intensity and duration.
  • inventions of the disclosure may be referred to herein, individually and/or collectively, by the term “invention” merely for convenience and without intending to voluntarily limit the scope of this application to any particular invention or inventive concept.
  • inventions merely for convenience and without intending to voluntarily limit the scope of this application to any particular invention or inventive concept.
  • specific embodiments have been illustrated and described herein, it should be appreciated that any subsequent arrangement designed to achieve the same or similar purpose may be substituted for the specific embodiments shown.
  • This disclosure is intended to cover any and all subsequent adaptations or variations of various embodiments. Combinations of the above embodiments, and other embodiments not specifically described herein, will be apparent to those of skill in the art upon reviewing the description.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Dentistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Audiology, Speech & Language Pathology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)

Abstract

L'invention concerne un système et un procédé d'évaluation de la santé d'un tissu. Le système comprend une source de lumière adaptée pour transmettre de la lumière ayant une longueur d'onde d'excitation au tissu. Le système comprend également un dispositif comprenant un matériau comprenant des points fluorescents (Fdots) disposés à l'intérieur de celui-ci. Les Fdots sont adaptés pour émettre une fluorescence à une longueur d'onde d'émission lorsque la lumière ayant la longueur d'onde d'excitation est incidente sur eux, et pour terminer la fluorescence en présence d'oxyde nitrique (NO). Le système comprend également une mémoire qui stocke des instructions ; et un processeur qui exécute les instructions. Lorsqu'elles sont exécutées par le processeur, les instructions amènent le système à : ajuster une sortie de la source de lumière à la longueur d'onde d'excitation pour traiter le tissu avec la lumière à la longueur d'onde d'émission sur la base d'un emplacement du NO et/ou d'un moment où le NO est présent.
PCT/EP2025/062434 2024-05-14 2025-05-07 Système d'évaluation de la santé tissulaire Pending WO2025237757A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202463647197P 2024-05-14 2024-05-14
US63/647,197 2024-05-14

Publications (1)

Publication Number Publication Date
WO2025237757A1 true WO2025237757A1 (fr) 2025-11-20

Family

ID=95699157

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2025/062434 Pending WO2025237757A1 (fr) 2024-05-14 2025-05-07 Système d'évaluation de la santé tissulaire

Country Status (1)

Country Link
WO (1) WO2025237757A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110275978A1 (en) * 2007-10-30 2011-11-10 Hyde Roderick A Devices and systems that deliver nitric oxide
US20120010683A1 (en) * 2008-12-31 2012-01-12 Koninklijke Philips Electronics N.V. method and apparatus for controlling a process of injury therapy
CN102585417A (zh) * 2012-01-04 2012-07-18 武汉理工大学 量子点/聚合物复合一氧化氮荧光探针及其制备方法
US20200246179A1 (en) * 2015-12-21 2020-08-06 Gholam A. Peyman Cancer Treatment Methods Using Thermotherapy And/Or Enhanced Immunotherapy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110275978A1 (en) * 2007-10-30 2011-11-10 Hyde Roderick A Devices and systems that deliver nitric oxide
US20120010683A1 (en) * 2008-12-31 2012-01-12 Koninklijke Philips Electronics N.V. method and apparatus for controlling a process of injury therapy
CN102585417A (zh) * 2012-01-04 2012-07-18 武汉理工大学 量子点/聚合物复合一氧化氮荧光探针及其制备方法
US20200246179A1 (en) * 2015-12-21 2020-08-06 Gholam A. Peyman Cancer Treatment Methods Using Thermotherapy And/Or Enhanced Immunotherapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CAI HAO ET AL: "Lysosome-targeted carbon dots with a light-controlled nitric oxide releasing property for enhanced photodynamic therapy", CHINESE CHEMICAL LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 35, no. 4, 19 August 2023 (2023-08-19), XP087486492, ISSN: 1001-8417, [retrieved on 20230819], DOI: 10.1016/J.CCLET.2023.108946 *

Similar Documents

Publication Publication Date Title
Garcez et al. Methylene blue and hydrogen peroxide for photodynamic inactivation in root canal-a new protocol for use in endodontics
Andreozzi et al. Camera selection for real‐time in vivo radiation treatment verification systems using Cherenkov imaging
JP2000516504A (ja) 薬剤の規則的摂取の監視システム
Salas et al. Monoclinic ZrO2 as a broad spectral response thermoluminescence UV dosemeter
CN107528998A (zh) 摄像装置
Coutinho et al. Comparison of temperature increase in in vitro human tooth pulp by different light sources in the dental whitening process
Carvalho et al. Use of laser fluorescence in dental caries diagnosis: a fluorescence x biomolecular vibrational spectroscopic comparative study
Walsh et al. Ultraviolet-induced fluorescence: shedding new light on dental biofilms and dental caries
Kekkonen et al. Chemical imaging of human teeth by a time-resolved Raman spectrometer based on a CMOS single-photon avalanche diode line sensor
Yakovliev et al. Noninvasive temperature measurement in dental materials using Nd3+, Yb3+ doped nanoparticles emitting in the near infrared region
Ou-Yang The application of ultra-weak photon emission in dermatology
Amaechi et al. Fluorescence and near-infrared light transillumination
WO2025237757A1 (fr) Système d'évaluation de la santé tissulaire
JP2024026065A (ja) リンパ節及びリンパ管イメージングのためのシステム及び方法
WO2025237867A1 (fr) Système d'évaluation de la santé tissulaire
WO2025237725A1 (fr) Dispositif d'évaluation de la santé tissulaire
Wu et al. Quantitative Assessment of Age-dependent changes in Porphyrins from fluorescence images of Ultraviolet Photography by Image Processing
Ankri et al. On Phantom experiments of the photon migration model in tissues
Weingarten et al. Correlation of near infrared absorption and diffuse reflectance spectroscopy scattering with tissue neovascularization and collagen concentration in a diabetic rat wound healing model
Park et al. Sensitivity and stability of optically stimulated luminescence dosimeters with filled deep electron/hole traps under pre-irradiation and bleaching conditions
US11141086B2 (en) Silicon photomultiplier array-based multispectral optical probes for image-guided radiotherapy
Kruijt et al. Monitoring ALA‐induced PpIX photodynamic therapy in the rat esophagus using fluorescence and reflectance spectroscopy
WO2007079943A1 (fr) Système capteur de fluorescence à fibre optique
Moseley et al. Does surface preparation alter ALA uptake in superficial non‐melanoma skin cancer in vivo?
Zdrada‐Nowak et al. Hyperspectral assessment of acne skin exposed to intense pulsed light (IPL) intense pulsed light in acne treatment